Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy — BIO-TIMER

Leukemia,Myeloid, Chronic Clinical Trial

Official title:
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.

Status Recruiting

Clinical Trial Summary

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Frailty
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia,Myeloid, Chronic

Clinical Trial Details

NCT number	NCT06130787
Study type	Interventional
Source	University Hospital, Clermont-Ferrand
Contact	Lise LACLAUTRE
Phone	+33473754963
Email	promo_interne_drci@chu-clermontferrand.fr
Status	Recruiting
Phase	N/A
Start date	November 17, 2023
Completion date	November 17, 2028

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05154474` - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Completed	`NCT00027144` - Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase	Phase 1
Recruiting	`NCT05143840` - Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase	Phase 2